Polypeptide Targeting in NSCLC to Overcome Therapy Resistance

Instead of continuously administering the same targeted therapy and waiting for resistance, the patent inverts the approach by using combination therapies that target multiple pathways simultaneously (EGFR inhibition combined with VEGF inhibition, PD-1/PD-L1 blockade, or chemotherapy). This multi-pronged attack prevents the cancer from developing resistance to any single agent, thereby maintaining treatment efficacy over longer periods.

The patent employs composite therapeutic regimens that combine multiple drugs with different mechanisms of action (e.g., erlotinib plus bevacizumab, or pembrolizumab plus chemotherapy). This composite approach leverages the synergistic effects of different therapies while mitigating the development of resistance to any single agent, thus extending the duration of therapeutic response.

The patent segments the diagnostic process into distinct components: (1) identification of specific biomarkers (EGFR mutations, ALK rearrangements, ROS1 fusions, PD-L1 expression), (2) selection of appropriate diagnostic tests for each biomarker type, and (3) integration of results to guide therapy. This segmentation allows clinicians to order only the necessary tests based on patient-specific factors, improving diagnostic accuracy without requiring all tests simultaneously.

The diagnostic approach is dynamic rather than static. The patent describes a stepwise process where initial biomarker testing guides first-line therapy selection, and subsequent testing is performed based on treatment response or progression. This dynamic adaptation of the diagnostic workup optimizes resource utilization while maintaining high diagnostic accuracy for guiding therapeutic decisions.